http://www.xconomy.com/boston/2009/03/16/8m-for-nkt-therapeutics/ Business + Technology in the Exponential Economy Sat, 11 Feb 2012 03:54:18 +0000 hourly 1 http://wordpress.org/?v=3.0.4 http://www.xconomy.com/boston/2009/03/16/8m-for-nkt-therapeutics/comment-page-1/#comment-50631 Today’s Financings and Deals: Innovatis, NKT Therapeutics, SFJ Pharma | IguanaBio - A Daily Biotech and Pharma Tabloid - Gossip, News, Humor and Updates on the Latest Events in the Biotechnology and Pharmaceutical Industries Tue, 17 Mar 2009 00:57:19 +0000 http://www.xconomy.com/?p=16306#comment-50631 [...] -NKT Therapeutics announced that it received $8M in venture financing from SV Life Sciences and MedImmune Ventures. NKT is developing an antibody that targets the invariant T cell receptor which, depending on the effector function of the antibody, can either activate or deplete NKT cells. NKT plans to target asthma as well as cancer, autoimmune diseases, atopic dermatitis and vaccine adjuvants. [Xconomy] [...] [...] -NKT Therapeutics announced that it received $8M in venture financing from SV Life Sciences and MedImmune Ventures. NKT is developing an antibody that targets the invariant T cell receptor which, depending on the effector function of the antibody, can either activate or deplete NKT cells. NKT plans to target asthma as well as cancer, autoimmune diseases, atopic dermatitis and vaccine adjuvants. [Xconomy] [...]

]]>